A complete Australia research reference for tirzepatide — dual GIP/GLP-1 receptor agonism, published study data, and analytical documentation expectations.
What is tirzepatide?
Tirzepatide is a 39-amino-acid linear peptide engineered from the native GIP backbone with substitutions that confer dual receptor agonism and resistance to DPP-4 cleavage.
Mechanism of action
- Dual agonism at the GIP and GLP-1 receptors — both class B GPCRs.
What a complete tirzepatide COA shows
- Batch identifier and synthesis date
- HPLC purity (≥98% for research-grade material)
- LC-MS confirmed exact mass (4813.45 Da monoisotopic)
- Acetate or trifluoroacetate counterion content
- Bacterial endotoxin and residual solvents per analytical method
Frequently asked research questions
Is tirzepatide the same as semaglutide?
No. Semaglutide is a GLP-1 mono-agonist; tirzepatide is a dual GIP/GLP-1 agonist with a different backbone, mass, and pharmacology.
Research use only. Absorb Labs supplies materials strictly for in vitro and laboratory research. Nothing in this article constitutes medical, therapeutic, or dosage advice for human or animal use.
